

# Monica Morrow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9401135/publications.pdf>

Version: 2024-02-01

293  
papers

16,126  
citations

20759

60  
h-index

19690

117  
g-index

299  
all docs

299  
docs citations

299  
times ranked

14042  
citing authors

#	ARTICLE	IF	CITATIONS
1	Margin Width and Local Recurrence in Patients Undergoing Breast Conservation After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 484-492.	0.7	2
2	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253.	3.0	5
3	Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast Cancers. <i>Annals of Surgical Oncology</i> , 2022, 29, 1043-1048.	0.7	2
4	Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?. <i>Cancer</i> , 2022, 128, 471-478.	2.0	7
5	Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2022, 29, 1737-1745.	0.7	1
6	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 423-430.	1.1	6
7	ASO Visual Abstract: Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy With Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2022, 29, 1748-1749.	0.7	1
8	Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 2263-2272.	0.7	3
9	Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women. <i>Npj Breast Cancer</i> , 2022, 8, 15.	2.3	1
10	ASO Visual Abstract: Can We Successfully Deescalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma In Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 2273.	0.7	0
11	De-escalation in breast cancer surgery. <i>Npj Breast Cancer</i> , 2022, 8, 25.	2.3	13
12	ASO Visual Abstract: Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
13	The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 3810-3819.	0.7	11
14	Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2022, 29, 4127-4136.	0.7	5
15	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	0.9	22
16	Surgery and prophylactic surgery in hereditary breast cancer. <i>Breast</i> , 2022, 62, S63-S66.	0.9	4
17	ASO Visual Abstract: Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
18	Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 4753-4760.	0.7	5

#	ARTICLE	IF	CITATIONS
19	ASO Author Reflections: Undertreatment of Early-Stage Breast Cancer in Elderly Women Undergoing Lumpectomy Without Radiotherapy Increases the Risk of Locoregional Recurrence. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
20	Association of Radiation Timing with Long-Term Satisfaction and Health-Related Quality of Life in Prosthetic Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2022, 150, 32e-41e.	0.7	6
21	Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypNO Breast Cancer After Neoadjuvant Chemotherapy?â€”Reply. <i>JAMA Oncology</i> , 2022, , .	3.4	1
22	ASO Visual Abstract: Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women With Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
23	Addressing the problem of overtreatment in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 535-548.	1.1	4
24	Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancerâ€”Related Lymphedema. <i>JAMA Oncology</i> , 2022, 8, 1195.	3.4	26
25	The effect of tumor size on nodal disease burden in clinically node negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12575-e12575.	0.8	0
26	Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets. <i>JAMA Surgery</i> , 2022, 157, 702.	2.2	12
27	Adoption of SSO-ASTRO Margin Guidelines for Ductal Carcinoma in Situ: What Is the Impact on Use of Additional Surgery?. <i>Annals of Surgical Oncology</i> , 2021, 28, 295-302.	0.7	8
28	How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2021, 28, 287-294.	0.7	51
29	Routine Opioid Prescriptions Are Not Necessary After Breast Excisional Biopsy or Lumpectomy Procedures. <i>Annals of Surgical Oncology</i> , 2021, 28, 303-309.	0.7	8
30	Addressing the Dilemma of Contralateral Prophylactic Mastectomy With Behavioral Science. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-272.	0.8	9
31	Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. <i>British Journal of Anaesthesia</i> , 2021, 126, 367-376.	1.5	41
32	10-Year Breast Cancer Outcomes in Women â‰¥35 Years of Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1007-1018.	0.4	14
33	Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?. <i>Annals of Surgical Oncology</i> , 2021, 28, 1328-1335.	0.7	2
34	ASO Author Reflections: Residual Disease in the Breast After Neoadjuvant Chemotherapy Does Not Mandate Routine Post-Mastectomy Radiation Therapy/Regional Nodal Irradiation. <i>Annals of Surgical Oncology</i> , 2021, 28, 1336-1337.	0.7	0
35	Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype. <i>Annals of Surgical Oncology</i> , 2021, 28, 4245-4253.	0.7	31
36	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. <i>Annals of Surgical Oncology</i> , 2021, 28, 4256-4262.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. <i>Annals of Surgical Oncology</i> , 2021, 28, 5134-5140.	0.7	11
38	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. <i>Npj Breast Cancer</i> , 2021, 7, 18.	2.3	5
39	Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 617-624.	1.1	8
40	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 541-550.	0.7	13
41	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
42	Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision. <i>Modern Pathology</i> , 2021, 34, 1495-1506.	2.9	13
43	ASO Author Reflections: Rethinking Palpable Adenopathy as a Marker of High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6069-6070.	0.7	0
44	Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6060-6068.	0.7	9
45	Tumor-Nipple Distance of $\geq 1$ cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 6024-6029.	0.7	2
46	Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 112-119.	1.1	5
47	Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6044-6050.	0.7	14
48	Reply to: "Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?" <i>Annals of Surgical Oncology</i> , 2021, 28, 777-778.	0.7	3
49	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	0.8	62
50	Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 10517-10517.	0.8	0
51	Does timing of chemotherapy impact breast satisfaction after breast conservation therapy and mastectomy with immediate reconstruction?. <i>Journal of Clinical Oncology</i> , 2021, 39, 589-589.	0.8	0
52	Breast cancer. <i>Lancet</i> , The, 2021, 397, 1750-1769.	6.3	731
53	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. <i>Carcinogenesis</i> , 2021, 42, 1281-1292.	1.3	5
54	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	2.3	38

#	ARTICLE	IF	CITATIONS
55	Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2021, 28, 5507-5512.	0.7	4
56	Does preoperative MRI accurately stratify early-stage HER2+ breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 307-315.	1.1	3
57	ASO Visual Abstract: Margin Width and Local Recurrence in Patients Undergoing Breast Conservation after Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 584.	0.7	0
58	ASO Visual Abstract: Post-Discharge Non-Steroidal Anti-Inflammatory Drugs Are Not Associated with Risk of Hematoma After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2021, 28, 635-636.	0.7	0
59	Quality of Life and Breast Cancer Surgery. <i>JAMA Surgery</i> , 2021, 156, e213759.	2.2	1
60	ASO Author Reflections: Heroic Mastectomy for Chemoresistant Disease: A Complex Decision. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	0
61	Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. <i>Cancer</i> , 2021, 127, 1749-1757.	2.0	11
62	Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 105-112.	1.1	8
63	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event. <i>JAMA Oncology</i> , 2021, 7, 1851.	3.4	61
64	ASO Visual Abstract: Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast Cancers. <i>Annals of Surgical Oncology</i> , 2021, 28, 761-762.	0.7	0
65	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio $\leq 2.0$ and Average HER2 Copy Number $\geq 4.0$ and $\leq 6.0$ . <i>Archives of Pathology and Laboratory Medicine</i> . 2020, 144, 597-601.	1.2	10
66	Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 743-749.	0.7	8
67	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in 2011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	0.7	20
68	De-escalating Breast Cancer Surgery—Where Is the Tipping Point?. <i>JAMA Oncology</i> , 2020, 6, 183.	3.4	15
69	Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 344-351.	0.7	58
70	MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. <i>EBioMedicine</i> , 2020, 61, 103042.	2.7	68
71	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	5.1	34
72	Laterality and Patient-Reported Outcomes following Autologous Breast Reconstruction with Free Abdominal Tissue: An 8-Year Examination of BREAST-Q Data. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 964-975.	0.7	8

#	ARTICLE	IF	CITATIONS
73	How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4702-4710.	0.7	31
74	Changes in Reoperation After Publication of Consensus Guidelines on Margins for Breast-Conserving Surgery. <i>JAMA Surgery</i> , 2020, 155, e203025.	2.2	22
75	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 873-880.	1.1	8
76	Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4637-4642.	0.7	14
77	ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 693-694.	0.7	0
78	Breast Implant-associated Anaplastic Large Cell Lymphoma Incidence. <i>Annals of Surgery</i> , 2020, 272, 403-409.	2.1	47
79	ASO Author Reflections: Discharge Without Opioids After Lumpectomy with Sentinel Node Biopsy Should be the Norm, Not the Exception. <i>Annals of Surgical Oncology</i> , 2020, 27, 682-683.	0.7	0
80	ASO Author Reflections: Refining Risk Assessment in Node-Positive Breast Cancer Patients Eligible for Sentinel Lymph Node Biopsy Alone. <i>Annals of Surgical Oncology</i> , 2020, 27, 3593-3594.	0.7	0
81	Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4515-4522.	0.7	55
82	Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3585-3592.	0.7	9
83	ASO Author Reflections: Axillary Staging in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy—Beyond Clinical Trials. <i>Annals of Surgical Oncology</i> , 2020, 27, 4523-4524.	0.7	1
84	Response to: “Letter to the Editor: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Miscalculation of Sensitivity and False Negative Rate”. <i>Annals of Surgical Oncology</i> , 2020, 27, 918-918.	0.7	0
85	Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 159-166.	1.1	18
86	ASO Author Reflections: To Dissect or Not to Dissect—The Clinical Implications of Microscopic Extracapsular Extension in the Sentinel Node. <i>Annals of Surgical Oncology</i> , 2020, 27, 1625-1626.	0.7	0
87	Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 197-205.	1.1	11
88	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, e196400.	3.4	32
89	Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. <i>Practical Radiation Oncology</i> , 2020, 10, e357-e362.	1.1	4
90	Postmastectomy Breast Reconstruction: Exploring Plastic Surgeon Practice Patterns and Perspectives. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 865-876.	0.7	32

#	ARTICLE	IF	CITATIONS
91	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ—Reply. <i>JAMA Oncology</i> , 2020, 6, 1118.	3.4	3
92	Locoregional Management After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2281-2289.	0.8	35
93	Statistical machine learning model to predict Oncotype DX risk category in women over age 50.. <i>Journal of Clinical Oncology</i> , 2020, 38, 524-524.	0.8	0
94	Association of intraoperative opioids with improved recurrence-free survival in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 542-542.	0.8	1
95	How much is too much? Multidisciplinary management of elderly early-stage breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12525-e12525.	0.8	0
96	Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.. <i>Journal of Clinical Oncology</i> , 2020, 38, 273-273.	0.8	0
97	Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. <i>Annals of Surgical Oncology</i> , 2019, 26, 3282-3288.	0.7	19
98	A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2019, 26, 3133-3140.	0.7	60
99	Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. <i>Annals of Surgical Oncology</i> , 2019, 26, 3269-3274.	0.7	10
100	ASO Author Reflections: A Negative Axillary Clinical Exam Adequately Identifies Clinically Node-Positive Patients who Downstage After NAC and are Candidates for SLNB. <i>Annals of Surgical Oncology</i> , 2019, 26, 4244-4245.	0.7	0
101	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4264-4271.	0.7	19
102	Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3856-3862.	0.7	11
103	Letter to Editor re: Ridner et al.: “A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis” <i>Annals of Surgical Oncology</i> , 2019, 26, 863-864.	0.7	4
104	ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era. <i>Annals of Surgical Oncology</i> , 2019, 26, 715-716.	0.7	2
105	Crafting a <i>JAMA Oncology</i> Clinical Challenge. <i>JAMA Oncology</i> , 2019, 5, 1695.	3.4	0
106	Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. <i>Annals of Surgical Oncology</i> , 2019, 26, 4238-4243.	0.7	22
107	Reply to “Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas” <i>Annals of Surgical Oncology</i> , 2019, 26, 310-311.	0.7	1
108	Does race predict survival for women with invasive breast cancer?. <i>Cancer</i> , 2019, 125, 3139-3146.	2.0	30

#	ARTICLE	IF	CITATIONS
109	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	1.1	42
110	Is Sentinel Lymph Node Biopsy Required for a Core Biopsy Diagnosis of Ductal Carcinoma In Situ with Microinvasion?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2738-2746.	0.7	13
111	Undissected Axilla and Axillary Radiotherapyâ€”In Reply. <i>JAMA Oncology</i> , 2019, 5, 742.	3.4	0
112	Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose?. <i>Annals of Surgical Oncology</i> , 2019, 26, 969-975.	0.7	24
113	Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. <i>Annals of Surgical Oncology</i> , 2019, 26, 2127-2135.	0.7	37
114	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. <i>Annals of Surgical Oncology</i> , 2019, 26, 2136-2143.	0.7	30
115	Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: A Meta-analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 1238-1244.	0.7	59
116	Differences in degree of lesion enhancement on CEM between ILC and IDC. <i>BJR   Open</i> , 2019, 1, 20180046.	0.4	11
117	Patterns and Correlates of Knowledge, Communication, and Receipt of Breast Reconstruction in a Modern Population-Based Cohort of Patients with Breast Cancer. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 303-313.	0.7	23
118	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
119	Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesityâ€”breast cancer connection. <i>Journal of Biological Chemistry</i> , 2019, 294, 361-371.	1.6	18
120	Guidelines Do Not Proscribe Surgeons Performing Genetic Testingâ€”Reply. <i>JAMA Surgery</i> , 2019, 154, 269.	2.2	0
121	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. <i>Annals of Surgical Oncology</i> , 2019, 26, 329-335.	0.7	9
122	Reducing Overtreatment of Cancer With Precision Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1091.	3.8	24
123	The 21-Gene Recurrence Score in Male Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1530-1535.	0.7	14
124	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1237-1245.	0.4	10
125	Margins in breast cancer: How much is enough?. <i>Cancer</i> , 2018, 124, 1335-1341.	2.0	88
126	Trend Analysis on Reoperation After Lumpectomy for Breast Cancerâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 747.	3.4	1



#	ARTICLE	IF	CITATIONS
127	Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1488-1494.	0.7	101
128	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1912-1920.	0.7	37
129	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. <i>Cancer</i> , 2018, 124, 46-54.	2.0	37
130	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	2.3	37
131	Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer. <i>JAMA Surgery</i> , 2018, 153, 29.	2.2	34
132	Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 659-666.	0.8	40
133	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1218-1224.	0.8	59
134	ASO Author Reflections: Low-Volume Sentinel Node Disease After Neoadjuvant Chemotherapy is Still an Indication for Axillary Dissection. <i>Annals of Surgical Oncology</i> , 2018, 25, 685-686.	0.7	3
135	Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. <i>Annals of Surgical Oncology</i> , 2018, 25, 3858-3866.	0.7	7
136	Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?. <i>Cancer</i> , 2018, 124, 4314-4321.	2.0	14
137	ASO Author Reflections: Biological Diversity of Histologic Subtypes. <i>Annals of Surgical Oncology</i> , 2018, 25, 636-637.	0.7	0
138	A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. <i>Annals of Surgical Oncology</i> , 2018, 25, 2909-2916.	0.7	70
139	Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. <i>Annals of Surgical Oncology</i> , 2018, 25, 2884-2889.	0.7	23
140	Overview of Breast Cancer Therapy. <i>PET Clinics</i> , 2018, 13, 339-354.	1.5	279
141	Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1511.	3.4	56
142	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 42.	1.1	9
143	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1066.	3.4	146
144	Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. <i>Annals of Surgical Oncology</i> , 2018, 25, 3158-3164.	0.7	26

#	ARTICLE	IF	CITATIONS
145	FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. <i>JCI Insight</i> , 2018, 3, .	2.3	34
146	Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1492-1498.	0.7	47
147	Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 645-651.	0.7	12
148	Reply to L.B. Marks et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1258-1259.	0.8	0
149	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017, 10, 235-243.	0.7	114
150	Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 275-282.	1.1	3
151	Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 531.	3.8	103
152	Leveraging the Benefits of Systemic Therapy to Tailor Surgery. <i>JAMA Surgery</i> , 2017, 152, 671.	2.2	4
153	Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2182-2188.	0.7	30
154	New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ. <i>Current Breast Cancer Reports</i> , 2017, 9, 122-128.	0.5	0
155	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1692-1701.	1.8	77
156	Axillary Nodal Management Following Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2017, 3, 549.	3.4	174
157	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2556-2562.	0.7	45
158	Trends in Reoperation After Initial Lumpectomy for Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1352.	3.4	100
159	Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 273-283.	1.1	156
160	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 65-76.	1.1	28
161	Editorial: Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	2
162	Patient Reactions to Surgeon Recommendations About Contralateral Prophylactic Mastectomy for Treatment of Breast Cancer. <i>JAMA Surgery</i> , 2017, 152, 658.	2.2	31

#	ARTICLE	IF	CITATIONS
163	Surgeon Attitudes and Use of MRI in Patients Newly Diagnosed with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1889-1896.	0.7	9
164	Are there patients with T1 to T2, lymph node-negative breast cancer who are at high risk for locoregional disease recurrence?. <i>Cancer</i> , 2017, 123, 2626-2633.	2.0	16
165	Recurrence risk perception and quality of life following treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 557-565.	1.1	51
166	Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. <i>JAMA Surgery</i> , 2017, 152, 274.	2.2	107
167	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 375-397.	0.7	61
168	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3888-3895.	0.7	13
169	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, 740-746.	0.2	77
170	Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3896-3902.	0.7	39
171	Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 918.	3.8	1,166
172	Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). <i>Annals of Surgical Oncology</i> , 2017, 24, 3141-3147.	0.7	22
173	The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. <i>Annals of Surgical Oncology</i> , 2017, 24, 3527-3533.	0.7	40
174	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2889-2897.	0.7	28
175	The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients. <i>Cancer</i> , 2017, 123, 4547-4555.	2.0	24
176	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. <i>Annals of Surgical Oncology</i> , 2017, 24, 568-569.	0.7	2
177	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 69-76.	1.1	31
178	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	2.1	90
179	De-escalating and escalating surgery in the management of early breast cancer. <i>Breast</i> , 2017, 34, S1-S4.	0.9	11
180	Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. <i>Annals of Surgical Oncology</i> , 2017, 24, 698-704.	0.7	39

#	ARTICLE	IF	CITATIONS
181	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. <i>Cancer</i> , 2017, 123, 131-137.	2.0	16
182	Why Are There So Many Mastectomies in the United States?. <i>Annual Review of Medicine</i> , 2017, 68, 229-241.	5.0	37
183	Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2232-2239.	0.8	212
184	Reply to "Implications of abnormal preoperative axillary imaging in the post 2011 era". <i>Gland Surgery</i> , 2016, 5, 453-454.	0.5	3
185	Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision. <i>Cancer</i> , 2016, 122, 2819-2827.	2.0	78
186	How Beneficial is Follow-Up Mammography in Elderly Breast Cancer Survivors?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3518-3523.	0.7	8
187	Society of Surgical Oncology "American Society for Radiation Oncology" American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016, 6, 287-295.	1.1	135
188	Trends and controversies in multidisciplinary care of the patient with breast cancer. <i>Current Problems in Surgery</i> , 2016, 53, 559-595.	0.6	7
189	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	0.7	232
190	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2016, 23, 2816-2824.	0.7	38
191	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 3481-3486.	0.7	25
192	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3487-3493.	0.7	66
193	Margins in DCIS: Does Residual Disease Provide an Answer?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3423-3425.	0.7	3
194	Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon. <i>Annals of Surgical Oncology</i> , 2016, 23, 2456-2461.	0.7	14
195	How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3475-3480.	0.7	29
196	Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 3459-3466.	0.7	20
197	The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 3811-3821.	0.7	130
198	Society of Surgical Oncology "American Society for Radiation Oncology" American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016, 34, 4040-4046.	0.8	211

#	ARTICLE	IF	CITATIONS
199	Society of Surgical Oncologyâ€™American Society for Radiation Oncologyâ€™American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016, 23, 3801-3810.	0.7	176
200	Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. <i>Immunity</i> , 2016, 45, 1122-1134.	6.6	507
201	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016, 34, 4431-4442.	0.8	182
202	Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center. <i>Annals of Surgical Oncology</i> , 2016, 23, 3239-3246.	0.7	62
203	Impact of Body Mass Index on Clinical Axillary Nodal Assessment in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 3324-3329.	0.7	21
204	Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman Spectroscopy. <i>Analytical Chemistry</i> , 2016, 88, 2140-2148.	3.2	22
205	Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. <i>Journal of the American College of Surgeons</i> , 2016, 222, 138-145.	0.2	68
206	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , 2016, 34, 2359-2365.	0.8	60
207	Reoperative Sentinel Lymph Node Biopsy is Feasible for Locally Recurrent Breast Cancer, But is it Worthwhile?. <i>Annals of Surgical Oncology</i> , 2016, 23, 744-748.	0.7	27
208	Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1123-1128.	0.7	82
209	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2283-2289.	3.2	154
210	Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 516.	3.4	4
211	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	0.7	121
212	Appropriate margin for lumpectomy excision of invasive breast cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 35-35.	0.4	11
213	Recurrence risk perception and quality of life after treatment of breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 175-175.	0.8	1
214	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 177-177.	0.8	0
215	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. <i>Annals of Surgery</i> , 2015, 262, 623-631.	2.1	94
216	Optimal surgical management for high-risk populations. <i>Breast</i> , 2015, 24, S91-S95.	0.9	7

#	ARTICLE	IF	CITATIONS
217	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. <i>Molecular Oncology</i> , 2015, 9, 772-782.	2.1	32
218	Current management of lesions associated with an increased risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 227-238.	12.5	110
219	Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 1518-1526.	0.7	114
220	Treatment Decision Making and Genetic Testing for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 997.	3.8	29
221	The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. <i>Annals of Surgical Oncology</i> , 2015, 22, 495-501.	0.7	44
222	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1666-1673.	3.3	79
223	Menopause Is a Determinant of Breast Adipose Inflammation. <i>Cancer Prevention Research</i> , 2015, 8, 349-358.	0.7	90
224	Concerns About Cancer Risk and Experiences With Genetic Testing in a Diverse Population of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1584-1591.	0.8	88
225	Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 335-343.	12.5	164
226	Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?. <i>Annals of Surgical Oncology</i> , 2015, 22, 470-475.	0.7	10
227	The Role of Axillary Node Dissection in the Post Z0011 Era. <i>Current Surgery Reports</i> , 2015, 3, 1.	0.4	0
228	Progress in the surgical management of breast cancer: Present and future. <i>Breast</i> , 2015, 24, S2-S5.	0.9	8
229	Addressing Overtreatment in DCIS: What Should Physicians Do Now?. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv290.	3.0	21
230	Comparison of <sup>18</sup> F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1674-1680.	2.8	92
231	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2015, 22, 3273-3281.	0.7	46
232	Rethinking the Local Therapy of Breast Cancer: Integration of Biology and Anatomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 3168-3173.	0.7	13
233	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.. <i>Journal of Clinical Oncology</i> , 2015, 33, 32-32.	0.8	1
234	Social and Clinical Determinants of Contralateral Prophylactic Mastectomy. <i>JAMA Surgery</i> , 2014, 149, 582.	2.2	146

#	ARTICLE	IF	CITATIONS
235	Access to Breast Reconstruction After Mastectomy and Patient Perspectives on Reconstruction Decision Making. JAMA Surgery, 2014, 149, 1015.	2.2	163
236	Bilateral implant reconstruction does not affect the quality of postmastectomy radiation therapy. Medical Dosimetry, 2014, 39, 18-22.	0.4	26
237	The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Therapy: A Meta-Analysis. Annals of Surgical Oncology, 2014, 21, 717-730.	0.7	397
238	The Effect of Margin Width on Local Recurrence of Triple Negative Breast Cancer. Current Breast Cancer Reports, 2014, 6, 32-37.	0.5	0
239	Applications for Breast Magnetic Resonance Imaging. Surgical Oncology Clinics of North America, 2014, 23, 431-449.	0.6	13
240	Retrospective Analysis of <sup>18</sup> F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years. Journal of Nuclear Medicine, 2014, 55, 1578-1583.	2.8	87
241	In Reply to Dixon and Thomas. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1139-1141.	0.4	3
242	The End of the Beginning: Society of Surgical Oncology 2013 Presidential Address. Annals of Surgical Oncology, 2014, 21, 1417-1425.	0.7	2
243	Society of Surgical Oncologyâ€”American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1507-1515.	0.8	369
244	Society of Surgical Oncologyâ€”American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 553-564.	0.4	364
245	Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer. Annals of Internal Medicine, 2013, 159, 373.	2.0	228
246	Case 8-2013. New England Journal of Medicine, 2013, 368, 1046-1053.	13.9	7
247	Long-Term Patient-Reported Satisfaction after Contralateral Prophylactic Mastectomy and Implant Reconstruction. Annals of Surgical Oncology, 2013, 20, 3422-3429.	0.7	75
248	Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2013, 20, 3469-3476.	0.7	125
249	Does preoperative MRI improve clinical outcomes in breast cancer?. Breast Cancer Management, 2013, 2, 115-122.	0.2	0
250	It Is Not Always Necessary to Do Axillary Dissection for T1 and T2 Breast Cancerâ€”Point. Cancer Research, 2013, 73, 7151-7154.	0.4	11
251	The Appropriate Extent of Surgery for Early-Stage Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 53-55.	1.8	4
252	MARGINS IN BREAST CANCER SURGERY. , 2012, , 65-85.		2

#	ARTICLE	IF	CITATIONS
253	MRI for breast cancer screening, diagnosis, and treatment. <i>Lancet, The</i> , 2011, 378, 1804-1811.	6.3	320
254	Occult Malignancy in Patients Undergoing Contralateral Prophylactic Mastectomy. <i>Annals of Surgery</i> , 2011, 254, 2-7.	2.1	32
255	Prophylactic mastectomy of the contralateral breast. <i>Breast</i> , 2011, 20, S108-S110.	0.9	27
256	Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2158-2164.	0.8	298
257	What is an Adequate Margin for Breast-Conserving Surgery? Surgeon Attitudes and Correlates. <i>Annals of Surgical Oncology</i> , 2010, 17, 558-563.	0.7	193
258	A prospective study of variability in mammographic density during the menstrual cycle. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 565-574.	1.1	32
259	Trends in the Surgical Treatment of Breast Cancer. <i>Breast Journal</i> , 2010, 16, S17-S19.	0.4	15
260	Reply to M.D. Lagios et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e220-e220.	0.8	1
261	Patterns and Correlates of Adjuvant Radiotherapy Receipt After Lumpectomy and After Mastectomy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2396-2403.	0.8	84
262	Magnetic Resonance Imaging for Screening, Diagnosis, and Eligibility for Breast-conserving Surgery: Promises and Pitfalls. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 475-492.	0.6	25
263	Surgeon Recommendations and Receipt of Mastectomy for Treatment of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1551.	3.8	297
264	Reply to A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer. <i>Cancer</i> , 2009, 115, 5846-5846.	2.0	0
265	The evolving role of axillary dissection. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 167-8.	0.3	0
266	Local Therapy and Survival in Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2399-2405.	13.9	287
267	RESPONSE: Re: Ductal Lavage Findings in Women With Known Breast Cancer Undergoing Mastectomy. <i>Journal of the National Cancer Institute</i> , 2005, 97, 857-858.	3.0	0
268	Patterns and Correlates of Local Therapy for Women With Ductal Carcinoma-In-Situ. <i>Journal of Clinical Oncology</i> , 2005, 23, 3001-3007.	0.8	86
269	Patient Involvement in Surgery Treatment Decisions for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5526-5533.	0.8	298
270	Residual Disease in DCIS. <i>Cancer Journal (Sudbury, Mass )</i> , 2003, 9, 31-32.	1.0	1



#	ARTICLE	IF	CITATIONS
271	Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma. Ca-A Cancer Journal for Clinicians, 2002, 52, 277-300.	157.7	283
272	Standard for the Management of Ductal Carcinoma In Situ of the Breast (DCIS). Ca-A Cancer Journal for Clinicians, 2002, 52, 256-276.	157.7	132
273	Changes in breast cancer therapy because of pathology second opinions. , 2002, 9, 982.		6
274	Expression of Epithelial Mucins MUC1, MUC2, and MUC3 in Ductal Carcinoma In Situ of the Breast. Breast Journal, 2001, 7, 40-45.	0.4	25
275	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment, 2001, 65, 125-134.	1.1	629
276	National Cancer Data Base survey of breast cancer management for patients from low income zip codes. Cancer, 2000, 88, 933-945.	2.0	55
277	The National Cancer Data Base: What does it mean to the community surgeon?. , 2000, 73, 189-191.		2
278	Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman. Annals of Surgical Oncology, 2000, 7, 67-71.	0.7	6
279	Management of the axillary nodes. Breast Cancer, 1999, 6, 1-12.	1.3	7
280	A Survival Benefit From Axillary Dissection: Was Halsted Correct?. Annals of Surgical Oncology, 1999, 6, 17-18.	0.7	30
281	Understanding ductal carcinoma in situ. Cancer, 1999, 86, 375-377.	2.0	14
282	Understanding ductal carcinoma in situ. Cancer, 1999, 86, 375-377.	2.0	2
283	Evaluation of common breast problems: guidance for primary care providers. Ca-A Cancer Journal for Clinicians, 1998, 48, 49-63.	157.7	40
284	The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer, 1998, 83, 1262-1273.	2.0	191
285	Accuracy of AJCC staging for breast cancer patients undergoing re-excision for positive margins. Annals of Surgical Oncology, 1998, 5, 719-723.	0.7	15
286	Axillary Dissection: An Obsolete Operation?. Breast Journal, 1998, 4, 330-335.	0.4	13
287	Tamoxifen for Breast Cancer Prevention: Ready for Prime Time?. Breast Journal, 1998, 4, 407-408.	0.4	3
288	The Role of Galactography in Patients with Postoperative Nipple Discharge. Breast Journal, 1997, 3, 74-76.	0.4	1

#	ARTICLE	IF	CITATIONS
289	Stereotactic Core-Needle Biopsy of the Breast: A Report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. Breast Journal, 1997, 3, 317-330.	0.4	4
290	Role of axillary dissection in breast cancer management. Annals of Surgical Oncology, 1996, 3, 233-234.	0.7	64
291	Axillary dissection: When and how radical?. , 1996, 12, 321-327.		32
292	The natural history of ductal carcinoma in situ. Implications for clinical decision making. Cancer, 1995, 76, 1113-1115.	2.0	16
293	Clinical Applications of Stereotactic Biopsy. Breast Journal, 1995, 1, 326-329.	0.4	0